Patents by Inventor Bruce L. Frank

Bruce L. Frank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090306003
    Abstract: An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphophilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a second compound. Compositions based on the microblend and methods of using the compositions to control pests are also disclosed.
    Type: Application
    Filed: January 10, 2007
    Publication date: December 10, 2009
    Applicant: Innovation Technologies, LLC
    Inventors: Alexander V. Kabanov, Tatiana K. Bronitch, Michael Karas, Bruce L. Frank
  • Patent number: 7060500
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2?-O-methyl ribonucleotides.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: June 13, 2006
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Patent number: 6984729
    Abstract: The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions.
    Type: Grant
    Filed: July 28, 1997
    Date of Patent: January 10, 2006
    Assignee: Hybridon, Inc.
    Inventors: Bruce L. Frank, Peter C. Roberts, John Goodchild, J. Charles Craig, John S. Mills, Andrew Slade, Robert E. Kilkuskie, Noel A. Roberts, Raymond Jupp
  • Publication number: 20040023392
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.
    Type: Application
    Filed: November 12, 2002
    Publication date: February 5, 2004
    Applicant: ValiGen (US), Inc.
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Publication number: 20030055240
    Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.
    Type: Application
    Filed: May 1, 2002
    Publication date: March 20, 2003
    Inventors: Peter C. Roberts, Bruce L. Frank, David E. Szymkowski, John S. Mills, John Goodchild, Jia L. Wolfe, Robert E. Kilkuskie, Isobel M. Greenfield, Veronica Sullivan
  • Patent number: 6509149
    Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 21, 2003
    Assignee: Hybridon, Inc.
    Inventors: Peter C. Roberts, Bruce L. Frank, David E. Szymkowski, John S. Mills, John Goodchild, Jia L. Wolfe, Robert E. Kilkuskie, Isobel M. Greenfield, Veronica Sullivan
  • Patent number: 6479292
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in animal, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammalian cells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: November 12, 2002
    Assignee: ValiGen (US), Inc.
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Patent number: 6458940
    Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.
    Type: Grant
    Filed: July 2, 1997
    Date of Patent: October 1, 2002
    Assignee: Hybridon, Inc.
    Inventors: Peter C. Roberts, Bruce L. Frank, David E. Szymkowski, John S. Mills, John Goodchild, Jia L. Wolfe, Robert E. Kilkuskie, Isobel M. Greenfield, Veronica Sullivan
  • Publication number: 20020081577
    Abstract: The present invention discloses synthetic oligonucleotides complementary to contiguous and non-contiguous regions of the HCV RNA. Also disclosed are methods and kits for inhibiting the replication of HCV, inhibiting the expression of HCV nucleic acid and protein, and for treating HCV infections.
    Type: Application
    Filed: July 2, 1997
    Publication date: June 27, 2002
    Inventors: ROBERT L. KILKUSKIE, BRUCE L. FRANK, JOHN GOODCHILD, JIA L. WOLFE, PETER C. ROBERTS, HENRY A. HAMLIN, NOEL A. ROBERTS, DEBRA M. WALTHER
  • Publication number: 20020068820
    Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.
    Type: Application
    Filed: June 6, 1995
    Publication date: June 6, 2002
    Inventors: PETER C. ROBERTS, BRUCE L. FRANK, DAVID E. SZYMKOWSKI, JOHN S. MILLS, JOHN GOODCHILD, JIA L. WOLFE, ROBERT E. KILKUSKIE, ISOBEL M. GREENFIELD, VERONICA SULLIVAN
  • Patent number: 6271360
    Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in mammalian, avian, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammaliancells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: August 7, 2001
    Assignee: ValiGen (US), Inc.
    Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
  • Publication number: 20010010899
    Abstract: The present invention discloses synthetic oligonucleotides complementary to a nucleic acid spanning the translational start site of human papillomavirus gene E1, and including at least 15 nucleotides. Also disclosed are methods and kits for inhibiting the replication of HPV, for inhibiting the expression of HPV nucleic acid and protein, for detection of HPV, and for treating HPV infections.
    Type: Application
    Filed: July 2, 1997
    Publication date: August 2, 2001
    Inventors: PETER C ROBERT, BRUCE L. FRANK, DAVID E. SZYMKOWSKI, JOHN S. MILLS, JOHN GOODCHILD, JIA L. WOLFE, ROBERT E. KILKUSKIE, ISOBEL M. GREENFIELD, VERONIA SULLIVAN
  • Patent number: 5856459
    Abstract: The present invention discloses synthetic oligonucleotides complementary to contiguous and noncontiguous regions of the HBV RNA. Also disclosed are methods and kits for inhibiting the replication and expression of HBV, and for treating HBV infections and associated conditions.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 5, 1999
    Assignee: Hybridon, Inc.
    Inventors: Bruce L. Frank, Peter C. Roberts, John Goodchild, J. Charles Craig, John S. Mills